Bifidobacterium pseudocatenulatum Ameliorates DSS-Induced Colitis by Maintaining Intestinal Mechanical Barrier, Blocking Proinflammatory Cytokines, Inhibiting TLR4/NF-κB Signaling, and Altering Gut Microbiota

This study was designed to explore the effects and discrepancy of different CLA-producing Bifidobacterium pseudocatenulatum on relieving colitis and to investigate the potential mechanisms. B. pseudocatenulatum MY40C and CCFM680 were administered to mice with DSS-induced colitis. The content of tight junction proteins and mucin2 was significantly upregulated. TNF-alpha and IL-6 were downregulated, while IL-10 and PPAR-gamma were upregulated. TLR4/NF-kappa B pathway activation was significantly inhibited. Moreover, each treated strain increased Allobaculum and decreased Sutterella, Bacteroides, and Oscillospira. The colonic conjugated linoleic acid (CLA) concentrations were significantly and positively correlated with the effectiveness of strain in relieving colitis. In conclusion, MY40C and CCFM680 supplementation alleviated DSS-induced colitis by protecting intestinal mechanical barrier, modulating gut microbiota, blocking proinflammatory cytokines, and inhibiting TLR4/NF-kappa B pathway. These results are conducive to promote clinical trials and product development of probiotics for colitis.

Automated summary

This study found that supplementation with B. pseudocatenulatum strains MY40C and CCFM680 alleviated DSS-induced colitis by protecting the intestinal mechanical barrier, modulating gut microbiota, blocking proinflammatory cytokines, and inhibiting the TLR4/NF-kappa B pathway.